Literature DB >> 16037145

Remifentanil as a single drug for extracorporeal shock wave lithotripsy: a comparison of infusion doses in terms of analgesic potency and side effects.

Hector J Medina1, Eilish M Galvin, Maaike Dirckx, Preveen Banwarie, Johannes F H Ubben, Freek J Zijlstra, Jan Klein, Serge J C Verbrugge.   

Abstract

UNLABELLED: This randomized, double-blind study was designed to evaluate analgesic effectiveness and side effects of two remifentanil infusion rates in patients undergoing extracorporeal shock wave lithotripsy (ESWL) for renal stones. We included 200 patients who were administered remifentanil either 0.05 microg x kg(-1) x min(-1) (n = 100) or 0.1 microg x kg(-1) x min(-1) (n = 100) plus demand bolus of 10 microg of remifentanil via a patient-controlled analgesia (PCA) device. No other sedating drugs were given. The frequencies of PCA demands and deliveries were recorded. Arterial blood pressure, oxygen saturation, and respiratory rate were recorded throughout the procedure; postoperative nausea and vomiting (PONV), dizziness, itching, agitation, and respiratory depression were measured posttreatment. Visual analog scale (VAS) scores were taken preoperatively, directly postoperatively, and 30 min after finishing the procedure. There were no statistically significant differences in the frequency of PCA demands and delivered boluses or among perioperative VAS scores. The extent of PONV and frequency of dizziness and itching immediately after and dizziness 30 min after the end of treatment were significantly reduced in the smaller dose group. We conclude that a remifentanil regimen of 0.05 microg x kg(-1) x min(-1) plus 10 microg demands is superior to 0.1 microg x kg(-1) x min(-1) plus demands, as there was no difference in the VAS scores recorded between groups and it has a less frequent incidence of side effects in patients receiving ESWL. IMPLICATIONS: Remifentanil is an appropriate analgesic choice for patients undergoing extracorporeal shock wave lithotripsy (ESWL) therapy, as it has both fast onset and offset times. We studied remifentanil as a sole drug for ESWL and have shown that an infusion rate of 0.05 microg x kg-1 x min-1 plus patient-controlled analgesia demands of 10 microg provides adequate analgesia and has significantly less side effects than a dose of 0.1 microg x kg-1 x min-1 plus 10 microg demands.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16037145     DOI: 10.1213/01.ANE.0000159379.54705.84

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  12 in total

1.  Sedation and analgesia in gastrointestinal endoscopy: what's new?

Authors:  Lorella Fanti; Pier-Alberto Testoni
Journal:  World J Gastroenterol       Date:  2010-05-28       Impact factor: 5.742

Review 2.  Patient-controlled analgesia in the management of postoperative pain.

Authors:  Mona Momeni; Manuela Crucitti; Marc De Kock
Journal:  Drugs       Date:  2006       Impact factor: 9.546

3.  Use of remifentanil for analgesia during dressing change in spontaneously breathing non-intubated burn patients.

Authors:  R Le Floch; E Naux; A Pilorget; J-F Arnould
Journal:  Ann Burns Fire Disasters       Date:  2006-09-30

Review 4.  [Remifentanil-based intraoperative anaesthesia and postoperative pain therapy. Is there an optimal treatment strategy?].

Authors:  C Zöllner; M Schäfer
Journal:  Anaesthesist       Date:  2007-10       Impact factor: 1.041

5.  Ketamine, propofol and low dose remifentanil versus propofol and remifentanil for ERCP outside the operating room: is ketamine not only a "rescue drug"?

Authors:  Lea Paola Fabbri; Maria Nucera; Massimo Marsili; Mohamed Al Malyan; Chiara Becchi
Journal:  Med Sci Monit       Date:  2012-09

6.  A comparison of three different target-controlled remifentanil infusion rates during target-controlled propofol infusion for oocyte retrieval.

Authors:  Demet Coskun; Berrin Gunaydin; Ayca Tas; Gozde Inan; Hulya Celebi; Kadir Kaya
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

7.  Drugs for pain management in shock wave lithotripsy.

Authors:  Christian Bach; Faruquz Zaman; Stefanos Kachrilas; Priyadarshi Kumar; Noor Buchholz; Junaid Masood
Journal:  Pain Res Treat       Date:  2011-11-03

8.  Analgesia for pain control during extracorporeal shock wave lithotripsy: Current status.

Authors:  Narmada P Gupta; Anup Kumar
Journal:  Indian J Urol       Date:  2008-04

9.  The Effect of EMLA Cream on Patient-Controlled Analgesia with Remifentanil in ESWL Procedure: A Placebo-Controlled Randomized Study.

Authors:  Arzu Acar; Elvan Erhan; M Nuri Deniz; Gulden Ugur
Journal:  Anesth Pain Med       Date:  2013-01-01

10.  Effects of midazolam or tramadol premedication on early cognitive function in endoscopic retrograde cholangiopancreatography (ERCP): A randomized, controlled, double-blind study.

Authors:  Hulya Ulusoy; Ilker Coskun; Mehmet Arslan
Journal:  J Int Med Res       Date:  2016-03-04       Impact factor: 1.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.